Jefferies Identifies 5 Top Biotech Stocks for Huge Upside
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
A new research report from Jefferies focuses on a set of growth stocks for this week that have big upside. These four have some serious upside potential.
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
The top analyst upgrades, downgrades and initiations seen on Monday, February 29, include Huntington Bancshares, Nucor, Orexigen Therapeutics, SanDisk, Square and VIVUS.
Investors really took to BioMarin Pharmaceuticals stock and there was a favorable jump after the fourth-quarter earnings report.
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added some color.
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Bluebird, Exxon Mobil, Kinder Morgan, Kinross Gold, Lending Club and Perrigo.
This week the Jefferies analysts are positive on companies that took a shot price-wise last week and may be offering an even better entry point for investors.
24/7 Wall St. tracked 15 fresh analyst calls in this past week alone in which analysts were calling for upside of almost 50% or more.